Bain Capital, LP is one of the world’s leading private multi-asset alternative investment firms with approximately $95 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact ir@baincapital.com.

Sign on to your account

Media Contacts

  • 12.18.17
    Life Sciences

    Aptinyx Raises $70 Million in Series B Financing to Advance Growing Pipeline through Clinical Studies in Neurologic Disorders

    EVANSTON, ILLINOIS, December 18, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline. The financing was led by Bain Capital Life Sciences. Additional new investors include Adage...

  • 10.13.17
    Life Sciences

    InflaRx announces a $55M Series D financing and investment round to foster its clinical stage complement anti-C5a development programs

    JENA, GERMANY, October 13, 2017 - InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today a $ 55M Series D financing and investment round. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC and complemented by certain investment funds managed by a leading US investment...

  • 9.25.17
    Double Impact
    Life Sciences

    SpringWorks Therapeutics Launches with $103M in Series A Funding and Rights to Four Clinical Programs

    NEW YORK, September 25, 2017 - SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its launch today with a completed $103 million Series A financing funded by Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer (NYSE:PFE) and LifeArc (formerly known as...

  • 9.8.17
    Life Sciences

    Replimune Raises $55 Million To Advance Its Oncolytic Immunotherapy Programs

    WOBURN, MA, September 8, 2017 – Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP1, in multiple tumor types. The financing will also allow the Company...

  • 3.30.17
    Life Sciences

    Solid Biosciences Raises up to $50 Million in Series C Financing

    CAMBRIDGE, MA, March 30, 2017 - Solid Biosciences announced today that it has completed the initial closing of its $50 Million Series C financing, which the company will use to progress its portfolio of programs targeted at Duchenne muscular dystrophy (DMD). The round was led by RA Capital Management and Bain Capital Life Sciences, together with funds from RTW Investments, Foresite Capital,...

  • 3.30.17
    Life Sciences

    Dicerna Secures $70 Million in Convertible Preferred Stock Financing

    CAMBRIDGE, MA, March 30, 2017 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) (the “Company”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a syndicate of current and new investors, led by Bain Capital Life Sciences, for the sale of redeemable convertible preferred stock...

Latest @BainCapital tweets